These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23735536)

  • 21. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment.
    Abate D; Tedla Y; Meressa D; Ameni G
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):946-51. PubMed ID: 25199009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of stock-outs of first line anti-tuberculosis drugs: the case of public health facilities of Addis Ababa city administration health bureau, Addis Ababa, Ethiopia.
    Sintayehu K; Zeleke ED; Temesgen B; Kifle M; Assefa DG; Zenebe K; Kassahun A; Yimer BT
    BMC Health Serv Res; 2022 Aug; 22(1):1047. PubMed ID: 35978406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia.
    Tessema B; Beer J; Emmrich F; Sack U; Rodloff AC
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):805-11. PubMed ID: 22390880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia.
    Abate D; Taye B; Abseno M; Biadgilign S
    BMC Res Notes; 2012 Aug; 5():462. PubMed ID: 22929063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The forest for the trees: tuberculosis control efforts in west Kalimantan.
    Shoeb M; Lopez de Castilla D; Pottinger P
    Trop Doct; 2011 Jan; 41(1):63-4. PubMed ID: 21109608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?
    Velayati AA; Farnia P; Masjedi MR; Hoffner S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):849-50. PubMed ID: 23676176
    [No Abstract]   [Full Text] [Related]  

  • 27. Multidrug-resistant Mycobacterium tuberculosis: a report of cosmopolitan microbial migration and an analysis of best management practices.
    Joean O; Thiele T; Schütz K; Schwerk N; Sedlacek L; Kalsdorf B; Baumann U; Stoll M
    BMC Infect Dis; 2020 Sep; 20(1):678. PubMed ID: 32942990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance of drug resistance tuberculosis based on reference laboratory data in Ethiopia.
    Diriba G; Kebede A; Tola HH; Alemu A; Tadesse M; Tesfaye E; Mehamed Z; Meaza A; Yenew B; Molalign H; Dagne B; Sinshaw W; Amare M; Moga S; Abebaw Y; Sied G
    Infect Dis Poverty; 2019 Jun; 8(1):54. PubMed ID: 31200748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization and drug resistance patterns of Mycobacterium tuberculosis complex in extrapulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Diriba G; Kebede A; Tola HH; Yenew B; Moga S; Addise D; Alemu A; Mohammed Z; Getahun M; Fantahun M; Tadesse M; Dagne B; Amare M; Assefa G; Abera D; Desta K
    PLoS One; 2020; 15(12):e0243493. PubMed ID: 33284842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
    Trials; 2020 May; 21(1):383. PubMed ID: 32370774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Provider reported barriers and solutions to improve testing among tuberculosis patients 'eligible for drug susceptibility test': A qualitative study from programmatic setting in India.
    Shewade HD; Kokane AM; Singh AR; Parmar M; Verma M; Desikan P; Khan SN; Kumar AMV
    PLoS One; 2018; 13(4):e0196162. PubMed ID: 29677210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming challenges in the diagnosis, prevention, and treatment of pediatric drug-resistant tuberculosis.
    Jonckheree S; Furin J
    Expert Rev Respir Med; 2017 May; 11(5):385-394. PubMed ID: 28319425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
    BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis.
    Shiferaw G; Woldeamanuel Y; Gebeyehu M; Girmachew F; Demessie D; Lemma E
    J Clin Microbiol; 2007 Apr; 45(4):1093-7. PubMed ID: 17251409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
    Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
    BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.
    Kurbatova EV; Cavanaugh JS; Shah NS; Wright A; Kim H; Metchock B; Van Deun A; Barrera L; Boulahbal F; Richter E; Martín-Casabona N; Arias F; Zemanova I; Drobniewski F; Santos Silva A; Coulter C; Lumb R; Cegielski JP
    Int J Tuberc Lung Dis; 2012; 16(3):355-7. PubMed ID: 22640449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs.
    Abate G; Miörner H; Ahmed O; Hoffner SE
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):580-4. PubMed ID: 9661826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newer Drugs for Tuberculosis Prevention and Treatment in Children.
    Marais BJ
    Indian J Pediatr; 2019 Aug; 86(8):725-731. PubMed ID: 30707347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic mass caused by Mycobacterium tuberculosis with reduced drug sensitivity.
    Small G; Wilks D
    J Infect; 2001 Apr; 42(3):201-2. PubMed ID: 11545552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary drug resistance to anti-tuberculosis drugs in major towns of Amhara region, Ethiopia.
    Yimer SA; Agonafir M; Derese Y; Sani Y; Bjune GA; Holm-Hansen C
    APMIS; 2012 Jun; 120(6):503-9. PubMed ID: 22583363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.